There's more to the deals than the big headline numbers.
News & Analysis: ASTELLAS PHARMA UNSP/ADR
Pfizer is paying $81.50 per share in cash to acquire Medivation's oncology drugs.
Rumors that a suitor might step up to acquire this mid cap cancer company sparked investor enthusiasm.
A top-selling cancer drug already on the market and more in the wings make this biotech a very attractive M&A target.
Weak growth for Zytiga may be due to stronger growth for Xtandi.
Bernie Sanders and other members of Congress have Medivation's Xtandi in the cross-hairs, but a decision on Xtandi could have wide-ranging implications for the industry and investors.
Congressmen have put Xtandi's price in their cross-hairs.
An earnings beat, mixed with upbeat guidance, puts the company's investors in a good mood.
Gilead Sciences, Biogen, Johnson & Johnson, Medivation, and Celgene have some of the fastest growing drugs in biotechnology.
Medivation stock is up more than 1,000% over the past three years and yet is still considered a cheap stock when using this Wall Street metric. Find out why Wall Street has fallen in love with Medivation, and whether or not the stock can head higher.